FDA gives big win to Amgen in biosimilars race
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Suit against SLO County challenges water policy
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Cottage-Sansum merger proposal tests virtues of integration
State and federal regulators are grappling with a deal that could reshape the region’s health care landscape. The proposed merger of Cottage Health, operator of the only hospitals in South Santa Barbara County and the Santa Ynez Valley, with Sansum Clinic, the largest physician practice in the area, raises questions about cost, quality and Read More →
Santa Barbara 100 bicycle ride aims to be world-class event
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Diablo Canyon Power Plant closure not a done deal
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Largest industrial building in Thousand Oaks sells for $37 million
The largest industrial building in Thousand Oaks was sold for $37 million, according to CBRE. Van Nuys-based real estate company Majestic Asset Management purchased the fully leased property at 1461-1475 Lawrence Drive from Austin, Texas-based Western National Life Insurance Co., a subsidiary of AIG. Majestic secured a $26.6 million balance sheet loan for the deal, Read More →
FDA approves Amgen biosimilar of AbbVie’s Humira
The Food and Drug Administration approved Amgen’s Humira biosimilar Sept. 23. Amjevita, formerly known as ABP 501 and made by Thousand Oaks-biotech giant Amgen, replicates the effects of Humira, which is approved to treat nine conditions including rheumatoid arthritis, skin disorders and colon inflammation. Humira, made by Chicago-based competitor AbbVie, typically costs $20,000 per year Read More →
